CPRX - Catalyst Pharmaceuticals, Inc.

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
Income Statement
Balance Sheet
Cash Flow

Income Statement

All numbers in thousands
Total Revenue---
Cost of Revenue---
Gross Profit---
Operating Expenses
Research Development11,375.23711,369.94111,801.342
Selling General and Administrative7,304.3997,910.268,597.01
Non Recurring---
Total Operating Expenses---
Operating Income or Loss-18,679.636-19,280.201-20,398.352
Income from Continuing Operations
Total Other Income/Expenses Net267.2591,207.749165.394
Earnings Before Interest and Taxes-18,412.377-18,072.452-20,232.958
Interest Expense---
Income Before Tax-18,412.377-18,072.452-20,232.958
Income Tax Expense---
Minority Interest---
Net Income From Continuing Ops-18,412.377-18,072.452-20,232.958
Non-recurring Events
Discontinued Operations---
Extraordinary Items---
Effect Of Accounting Changes---
Other Items---
Net Income
Net Income-18,412.377-18,072.452-20,232.958
Preferred Stock And Other Adjustments---
Net Income Applicable To Common Shares-18,412.377-18,072.452-20,232.958